|Table of Contents|

Research progress on the effect of MTHFR and TYMS gene polymorphisms on the toxicity of high-dose methotrexate chemotherapy

Journal Of Modern Oncology[ISSN:1672-4992/CN:61-1415/R]

Issue:
2025 06
Page:
1057-1061
Research Field:
Publishing date:

Info

Title:
Research progress on the effect of MTHFR and TYMS gene polymorphisms on the toxicity of high-dose methotrexate chemotherapy
Author(s):
LI Yongle1; YANG Liying1; YU Dongxu2; YANG Dongguang1
1.Dapartment of Hematology,the First Affiliated Hospital of Harbin Medical University,Heilongjiang Harbin 150000,China;2.Department of Infectious Disease,the Secend Hospital of Tianjin Medical University,Tianjin 300000,China.
Keywords:
acute lymphoblastic leukemia; high-dose methotrexate; MTHFR; TYMS; toxicity
PACS:
R730.5
DOI:
10.3969/j.issn.1672-4992.2025.06.025
Abstract:
Now,methotrexate(MTX) has become an important medicine of the consolidation and maintenance treatment of childhood acute lymphoblastic leukemia(ALL).High-dose methotrexate has a good therapeutic effect,but it also brings serious toxicity,such as liver toxicity,nephrotoxicity,bone marrow suppression,and mucosal damage.These toxicities are often the incentives for patients to give up treatment,and they are also one of the main reasons for the increase in recurrence and mortality of patients.There is evidence that the toxicity of methotrexate may be affected by genetic polymorphisms of methotrexate-related transporters and related metabolic enzymes.This paper mainly reviews the research progress on the effects of gene polymorphisms of methylenetetrahydrofolate reductase(MTHFR) and thymidylate synthase(TYMS) in methotrexate related metabolic enzymes on the toxicity of high-dose methotrexate in children with acute lymphoblastic leukemia.

References:

［1］BROWN P,INABA H,ANNESLEY C,et al.Pediatric acute lymphoblastic leukemia,version 2.2020,NCCN clinical practice guidelines in oncology［J］.Journal of the National Comprehensive Cancer Network,2020,18(1):81-112.
［2］FOA R,CHIARETTI S.Philadelphia chromosome-positive acute lymphoblastic leukemia［J］.N Engl J Med,2022,386(25):2399-2411.
［3］CHAE H,KIM M,CHOI SH,et al.Influence of plasma methotrexate level and MTHFR genotype in Korean paediatric patients with acute lymphoblastic leukaemia［J］.Journal of Chemotherapy,2020,32(5):251-259.
［4］CAMPBELL M,KISS C,ZIMMERMANN M,et al.Childhood acute lymphoblastic leukemia:Results of the randomized acute lymphoblastic leukemia intercontinental-Berlin-Frankfurt-Münster 2009 trial［J］.J Clin Oncol,2023,41(19):3499-3511.
［5］ESMAILI MA,KAZEMI A,FARANOUSH M,et al.Polymorphisms within methotrexate pathway genes:Relationship between plasma methotrexate levels,toxicity experienced and outcome in pediatric acute lymphoblastic leukemia［J］.Iranian Journal of Basic Medical Sciences,2020,23(6):800-809.
［6］ZHAO Z,HUA Z,LUO X,et al.Application and pharmacological mechanism of methotrexate in rheumatoid arthritis［J］.Biomed Pharmacother,2022,150:113074.
［7］RANA S,DRANCHAK P,DAHLIN JL,et al.Methotrexate-based PROTACs as DHFR-specific chemical probes［J］.Cell Chem Biol,2024,31(2):221-233.e14.
［8］UMEREZ M,GUTIERREZ-CAMINO A,MUNOZ-MALDONADO C,et al.MTHFR polymorphisms in childhood acute lymphoblastic leukemia:influence on methotrexate therapy［J］.Pharmacogenomics and Personalized Medicine,2017,10:69-78.
［9］SUTHANDIRAM S,GAN GG,ZAIN SM,et al.Effect of polymorphisms within methotrexate pathway genes on methotrexate toxicity and plasma levels in adults with hematological malignancies［J］.Pharmacogenomics,2014,15(11):1479-1494.
［10］SAJITH M,PAWAR A,BAFNA V,et al.Serum methotrexate level and side effects of high dose methotrexate infusion in pediatric patients with acute lymphoblastic leukaemia (ALL)［J］.Indian Journal of Hematology and Blood Transfusion,2020,36(1):51-58.
［11］GILETTI A,VITAL M,LORENZO M,et al.Methotrexate pharmacogenetics in Uruguayan adults with hematological malignant diseases［J］.European Journal of Pharmaceutical Sciences,2017,109:480-485.
［12］ZHAN M,LIU T,ZHANG Z,et al.Impact of microRNA polymorphisms on high-dose methotrexate-related hematological toxicities in pediatric acute lymphoblastic leukemia［J］.Front Pediatr,2023,11:1153767.
［13］XU M,WU S,WANG Y,et al.Association between high-dose methotrexate-induced toxicity and polymorphisms within methotrexate pathway genes in acute lymphoblastic leukemia［J］.Front Pharmacol,2022,13:1003812.
［14］MATEOS MK,MARSHALL GM,BARBARO PM,et al.Methotrexate-related central neurotoxicity:clinical characteristics,risk factors and genome-wide association study in children treated for acute lymphoblastic leukemia［J］.Haematologica,2022,107(3):635-643.
［15］OOSTEROM N,DE JONGE R,SMITH DEC,et al.Changes in intracellular folate metabolism during high-dose methotrexate and Leucovorin rescue therapy in children with acute lymphoblastic leukemia［J］.PLoS One,2019,14(9):e0221591.
［16］JIANG R,MEI S,ZHAO Z.Leucovorin (folinic acid) rescue for high-dose methotrexate:A review［J］.J Clin Pharm Ther,2022,47(9):1452-1460.
［17］KALUZNA E,STRAUSS E,ZAJAC-SPYCHALA O,et al.Functional variants of gene encoding folate metabolizing enzyme and methotrexate-related toxicity in children with acute lymphoblastic leukemia［J］.European Journal of Pharmacology,2015,769:93-99.
［18］FRIKHA R,JEMAA MB,FRIKHA F,et al.Involvement of C677T MTHFR variant but not A1298C in methotrexate-induced toxicity in acute lymphoblastic leukemia［J］.Journal of Oncology Pharmacy Practice,2021,27(6):1382-1387.
［19］GERVASINI G,MOTA-ZAMORANO S.Clinical implications of methotrexate pharmacogenetics in childhood acute lymphoblastic leukaemia［J］.Current Drug Metabolism,2019,20(4):313-330.
［20］CHANG XL,GUO YX,SU L,et al.Influence of MTHFR C677T polymorphism on high-dose methotrexate-related toxicity in patients with primary central nervous system diffuse large B-cell lymphoma［J］.Clinical Lymphoma Myeloma and Leukemia,2021,21(2):91-96.
［21］MOSTAFA-HEDEAB G,ELBORAI Y,EBID GTA.Effects of methylene tetrahydro folate reductase gene polymorphisms on methotrexate toxicity in egyptian pediatric acute lymphocytic leukaemia patients［J］.Iranian Journal of Pharmaceutical Research,2020,19(4):387-393.
［22］VAN DER POL KH,NIJENHUIS M,SOREE B,et al.Dutch pharmacogenetics working group guideline for the gene-drug interaction of ABCG2,HLA-B and allopurinol,and MTHFR,folic acid and methotrexate［J］.Eur J Hum Genet,2024,32(2):155-162.
［23］GUO Q,SUN JL,LI R,et al.Involvement of the ABCB1 C3435T variant but not the MTHFR C677T or MTHFR A1298C variant in high-dose methotrexate-induced toxicity in pediatric acute lymphoblastic leukemia patients in China［J］.Int J Gen Med,2024,17:1221-1231.
［24］YOUSEF AM,FARHAD R,ALSHAMASEEN D,et al.Folate pathway genetic polymorphisms modulate methotrexate-induced toxicity in childhood acute lymphoblastic leukemia［J］.Cancer Chemotherapy and Pharmacology,2019,83(4):755-762.
［25］WANG SM,ZENG WX,WU WS,et al.Genotype and allele frequencies of TYMS rs2790 A>G polymorphism in a Chinese paediatric population with acute lymphoblastic leukaemia［J］.Journal of Clinical Pharmacy and Therapeutics,2018,43(4):507-512.
［26］SEN A,KARATI D.An insight into thymidylate synthase inhibitor as anticancer agents:an explicative review［J］.Naunyn Schmiedebergs Arch Pharmacol,2024,397(8):5437-5448.
［27］AL-SHEIKH A,YOUSEF AM,ALSHAMASEEN D,et al.Effects of thymidylate synthase polymorphisms on toxicities associated with high-dose methotrexate in childhood acute lymphoblastic leukemia［J］.Cancer Chemother Pharmacol,2021,87(3):379-385.
［28］NAZKI FH,MASOOD A,BANDAY MA,et al.Thymidylate synthase enhancer region polymorphism not related to susceptibility to acute lymphoblastic leukemia in the Kashmir population［J］.Genetics and Molecular Research,2012,11(2):906-917.
［29］KOTUR N,LAZIC J,RISTIVOJEVIC B,et al.Pharmacogenomic markers of methotrexate response in the consolidation phase of pediatric acute lymphoblastic leukemia treatment［J］.Genes,2020,11(4):468.
［30］YANG L,HU X,XU LH.Impact of methylenetetrahydrofolate reductase (MTHFR) polymorphisms on methotrexate-induced toxicities in acute lymphoblastic leukemia:a meta-analysis［J］.Tumor Biology,2012,33(5):1445-1454.
［31］ZAHRA FT,NAHID NA,ISLAM MR,et al.Pharmacogenetic variants in MTHFR gene are significant predictors of methotrexate toxicities in Bangladeshi patients with acute lymphoblastic leukemia［J］.Clinical Lymphoma Myeloma and Leukemia,2020,20(2):e58-e65.
［32］FRIKHA R,REBAI T,LOBNA BM,et al.Comprehensive analysis of methylenetetrahydrofolate reductase C677T in younger acute lymphoblastic leukemia patients:A single-center experience［J］.Journal of Oncology Pharmacy Practice,2019,25(5):1182-1186.
［33］YAO PL,HE X,ZHANG R,et al.The influence of MTHFR genetic polymorphisms on adverse reactions after methotrexate in patients with hematological malignancies:a meta-analysis［J］.Hematology,2019,24(1):10-19.
［34］LOPEZ-LOPEZ E,MARTIN-GUERRERO I,BALLESTEROS J,et al.A systematic review and meta-analysis of MTHFR polymorphisms in methotrexate toxicity prediction in pediatric acute lymphoblastic leukemia［J］.The Pharmacogenomics Journal,2013,13(6):498-506.
［35］CWIKLINSKA M,CZOGALA M,KWIECINSKA K,et al.Polymorphisms of SLC19A1 80 G>A,MTHFR 677 C>T,and Tandem TS repeats influence pharmacokinetics,acute liver toxicity,and vomiting in children with acute lymphoblastic leukemia treated with high doses of methotrexate［J］.Frontiers in Pediatrics,2020,8:307.
［36］ZGHEIB NK,AKRA-ISMAIL M,ARIDI C,et al.Genetic polymorphisms in candidate genes predict increased toxicity with methotrexate therapy in Lebanese children with acute lymphoblastic leukemia［J］.Pharmacogenetics & Genomics,2014,24(8):387-396.
［37］NATANJA O,MARIJN B,DEN HOED MAH,et al.The role of genetic polymorphisms in the thymidylate synthase (TYMS) gene in methotrexate-induced oral mucositis in children with acute lymphoblastic leukemia［J］.Pharmacogenetics & Genomics,2018,28(10):223-229.

Memo

Memo:
-
Last Update: 1900-01-01